U.S. Markets closed

Cardiovascular Systems enrolls first patient in Liberty 360 study

Cardiovascular Systems announced that the first patient has been enrolled in its post-market study, Liberty 360 . The study is evaluating the acute and long-term clinical and economic outcomes of CSI's orbital atherectomy system in treating peripheral arterial disease, or PAD. Additionally, LIBERTY 360 is the first study of its kind to compare orbital atherectomy to all other PAD treatment options in a difficult-to-treat patient population.